Peripheral Nerve Society (PNS) Annual Meeting

Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.

Nester Tomycz, MD, director of neurosurgical pain division at Allegheny General Hospital, discussed emerging neurosurgerical approaches for chronic pain, with a focus on neuromodulation, patient selection, and non-opioid treatment pathways.

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.

Researchers reported that both EN001 and insulin improved muscle strength and nerve function in models of Charcot-Marie-Tooth disease type 1A, with combined treatment showing enhanced effects.

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.

New findings confirm vutrisiran's long-term safety and efficacy in treating hereditary transthyretin amyloidosis, enhancing patient quality of life.

The vice president and franchise lead of Autoimmune at Hansa Biopharma discussed the rapid, antibody-cleaving mechanism of imlifidase and its potential to address unmet needs in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

Gene therapy arsa-cel significantly improves nerve function in children with late-infantile metachromatic leukodystrophy, outperforming traditional treatments.

A recent matched cohort analysis revealed that patients with CIDP treated with immunoglobulin had lower rates of assistive device deterioration and opioid use compared with those untreated.

Matched analysis from the IGOS dataset showed ANX005-treated patients had greater improvements in GBS disability scores over time compared with those receiving IVIg or plasma exchange.

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, outlined the goals and significance of the VITALIZE and MOBILIZE phase 3 trials evaluating riliprubart in standard-of-care and treatment-refractory CIDP populations. [WATCH TIME: 3 minutes]

Subgroup data from a phase 2 CIDP trial showed riliprubart maintained consistent efficacy and safety across patient demographics, disease characteristics, and prior treatment exposures.

Findings suggest a potential correlation between motor function improvement and decreased autophagy-related protein levels in patients with spinal muscular atrophy treated with nusinersen.

A newly presented study showed that patients with sarcopenia before starting chemotherapy had a greater likelihood of developing moderate to severe peripheral neurotoxicity.

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, provided clinical context on sustained responses and new biomarker findings from exploratory phase 2 data on riliprubart in CIDP. [WATCH TIME: 4 minutes]

Eplontersen showed promise in halting disability progression and improving gait speed in patients with hereditary amyloid polyneuropathy, according to recent study findings.

A recently presented biobank data analysis showed associations between reduced transthyretin and higher incidence of conditions such as Alzheimer disease, cardiovascular disease, and rheumatoid arthritis.

Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.

A recently presented matching-adjusted indirect comparison assessed outcomes of immune globulin subcutaneous (Human)-ifas, 10% solution versus subcutaneous efgartigimod in patients with CIDP.

The president-elect of the Peripheral Nerve Society provided clinical context the mechanism and clinical relevance of riliprubart, a targeted complement inhibitor in development for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 3 minutes]

Carba1 showed promise in preclinical models as a dual-action agent, protecting against chemotherapy-induced neuropathy while preserving anticancer efficacy and safety.

Presented at the 2025 PNS Annual Meeting, phase 2 ARDA data showed empasiprubart reduced IVIg retreatment risk and improved grip strength in patients with MMN.

New data from a phase 2 study presented at the 2025 PNS Annual Meeting showed that riliprubart reduced plasma NfL levels in CIDP, with greater reductions linked to stronger functional improvements.

Patients with Guillain-Barré syndrome treated with tanruprubart, formerly known as ANX005, reported significant benefits in mobility, self-care, and usual activity compared with placebo.